WALVAX(SZ:300142)2018-10-22 16:00Financial Performance - Net profit attributable to shareholders reached ¥17,960,375.86, a significant increase of 385.16% year-on-year[9] - Operating revenue for the period was ¥198,795,826.89, reflecting an 11.48% growth compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,217,214.53, up 518.67% year-on-year[9] - Basic earnings per share increased to ¥0.0117, a rise of 387.50% compared to the same period last year[9] - The company's net profit for the period was ¥22,349,498.67, a significant increase from ¥300,632.47 in the previous period[56] - The net profit for the third quarter was a loss of CNY 14,171,006.53, slightly improved from a loss of CNY 14,948,517.73 in the previous year[57] - The net profit for the year-to-date period was CNY 108,726,674.85, compared to a loss of CNY 51,937,524.12 in the same period last year[61] Assets and Liabilities - Total assets increased to ¥6,937,660,852.39, representing an 18.07% increase compared to the previous year[9] - The company's total assets increased by 18.07% to RMB 693,766.09 million, with current assets accounting for 48.34% of total assets[19] - The total liabilities decreased by 16.99% to RMB 192,467.93 million compared to the previous year, reflecting a reduction in short-term borrowings and other liabilities[24] - Total liabilities decreased to ¥1,924,679,276.17 from ¥2,318,481,372.27, a reduction of approximately 17%[50] - The company's total non-current liabilities decreased by 9.55% to RMB 76,248.43 million, indicating a reduction in long-term obligations[24] Cash Flow - The company reported a net cash flow from operating activities of -¥91,114,266.51, a decline of 660.48% year-on-year[9] - The net cash flow from operating activities was -¥91,114,266.51, worsening from -¥11,981,171.55 in the previous period[67] - Cash inflow from investment activities reached 54,267.82 million RMB, an increase of 108.43% from 26,036.88 million RMB year-on-year, primarily due to new equity transfers[34] - Cash inflow from financing activities was 91,651.98 million RMB, up 125.30% from 40,680.00 million RMB in the previous year, driven by investments from minority shareholders[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,196[13] - The largest shareholder, Yunnan Provincial Industrial Investment Holding Group Co., Ltd., held 12.99% of the shares[13] Government Support and Subsidies - The company received government subsidies amounting to ¥9,362,292.20 during the reporting period[10] Inventory and Accounts Receivable - Accounts receivable at the end of the period reached RMB 41,486.25 million, an increase of RMB 11,763.06 million or 39.58%, driven by significant growth in sales of self-produced vaccine products[20] - The company's inventory at the end of the period was RMB 24,362.73 million, an increase of RMB 3,298.49 million or 15.66% compared to the previous year[19] Research and Development - Research and development expenses increased to ¥27,198,032.51 from ¥21,285,714.35, reflecting a growth of 27.9%[55] Future Outlook and Strategy - The company plans to continue expanding its vaccine production capabilities and exploring new investment opportunities in the healthcare sector[20] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2019[39] - Future guidance indicates a focus on increasing international sales, aiming for a 25% contribution to total revenue by 2020[39] Other Financial Metrics - The weighted average return on net assets was 0.52%, an increase of 0.12 percentage points from the previous year[9] - The gross margin for Q3 2018 improved to 45%, up from 40% in the same period last year[39] - The company reported a significant increase in other income, which rose to 486.89 million RMB, a 202770.83% increase from 0.24 million RMB in the previous year[31]